Arecor Therapeutics CEO Sarah Howell joined Proactive's Stephen Gunnion with details of a year-end trading update that outlined significant developments in the company's operations.
Key among these was the European market launch of the first product featuring Arecor's Arestat technology, AT220, marking a major technological validation and the commencement of royalty streams. The company has reported a notable 90% increase in gross revenue compared to the previous year, driven primarily by successful partnerships, licensing, and robust sales through Tetris Pharma.
Further cementing its position, Arecor has finalized patient enrollment for its proprietary diabetes product, AT278, and anticipates releasing crucial clinical data in the first half of 2024. The company's diverse portfolio includes two additional licensed products: AT307, a specialty hospital product developed in-house and licensed to Hikma Pharmaceuticals, and INBRX-101, a therapy for a rare disease under license with Inhibrx, recently subject to an acquisition intent by Sanofi.
Arecor's diabetes portfolio is also making strides, particularly with its concentrated, rapid-acting insulin study (AT278) focusing on type 2 diabetic patients with high BMI. This development is poised for data release in the first half of the year.
Additionally, the company's specialty pharmaceutical business, Tetris Pharma, has seen significant growth, with sales increasing from £1 million to £2.9 million, driven by the successful promotion of lead product, Ogluo. This treatment for severe hypoglycemia represents a substantial improvement in emergency care for diabetic patients.
Looking ahead, Arecor is focusing on further expanding its pipeline and partnership opportunities throughout 2024, with upcoming financial results to be detailed in April.
#ArecorTherapeutics #SarahHowell #HealthcareInnovation #BiotechIndustry #Arestat #DiabetesCare #PharmaceuticalDevelopment #ClinicalTrials #RevenueGrowth #TherapeuticAdvancements #TetrisPharma #HikmaPharmaceuticals #Inhibrx #Sanofi #Biopharmaceuticals #MedTech #HealthcareSector #DrugDevelopment #RapidActingInsulin #BiotechCEOInterview #ProactiveLondon #BiotechnologyNews #HealthcareInvestment #MedicalResearch #PharmaPartnerships #EmergingTherapies #BiotechTrends #Pharmaceuticals #HealthcareManagement #BiotechLeadership #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
